Quick Answer
ImmunityBio, Inc. reported R&D Expense of $190.14 million for fiscal year 2024.
ImmunityBio, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2024 | $190.14M | -18.2% |
| 2023 | $232.37M | -6.4% |
| 2022 | $248.15M | +26.6% |
| 2021 | $195.96M | +40.5% |
| 2020 | $139.51M | +24.6% |
| 2019 | $112.00M | +101.0% |
| 2018 | $55.72M | +32.5% |
| 2017 | $42.04M | +44.2% |
| 2016 | $29.15M | +155.0% |
| 2015 | $11.43M | +616.9% |
| 2014 | $1.59M | +257.6% |
| 2013 | $446.0K | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2024 | $50.44M | +4.2% | -1.3% |
| June 30, 2024 | $51.13M | -3.8% | -4.2% |
| March 31, 2024 | $53.35M | -32.7% | +10.2% |
| September 30, 2023 | $48.40M | -32.4% | -9.0% |
| June 30, 2023 | $53.17M | -15.7% | -32.9% |
| March 31, 2023 | $79.26M | +43.1% | +10.7% |
| September 30, 2022 | $71.61M | +45.3% | +13.5% |
| June 30, 2022 | $63.08M | +17.3% | +13.9% |
- ImmunityBio, Inc. showed a decrease of -18.2% in R&D Expense compared to the prior fiscal year.
- Over the 2013–2024 period, ImmunityBio, Inc.’s r&d expense has grown by 42533.2% (from $446.0 thousand to $190.14 million).
- The most recent figure is from ImmunityBio, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 3, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: